[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
From the Centers for Disease Control and Prevention
May 28, 2003

Updated Interim Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS)—United States, April 29, 2003

JAMA. 2003;289(20):2637-2639. doi:10.1001/jama.289.20.2637-a

MMWR. 2003;52:391-393

1 figure omitted

On April 29, 2003, this report was posted on the MMWR website (http://www.cdc.gov/mmwr). Before publication in this issue an error was corrected. In the last sentence of the second paragraph and in the § footnote of the box, the correct number of days should have been "≤21 days."

CDC's interim surveillance case definition for severe acute respiratory syndrome (SARS) has been updated to include laboratory criteria for evidence of infection with the SARS-associated coronavirus (SARS-CoV) (Figure , see sidebar). In addition, clinical criteria have been revised to reflect the possible spectrum of respiratory illness associated with SARS-CoV. Epidemiologic criteria have been retained. The majority of U.S. cases of SARS continue to be associated with travel (see footnote), with only limited secondary spread to household members or health-care providers.1

SARS has been associated etiologically with a novel coronavirus, SARS-CoV.2,3 Evidence of SARS-CoV infection has been identified in patients with SARS in several countries, including the United States. Several new laboratory tests can be used to detect SARS-CoV. Serologic testing for coronavirus antibody can be performed by using indirect fluorescent antibody or enzyme-linked immunosorbent assays that are specific for antibody produced after infection. Although some patients have detectable coronavirus antibody during the acute phase (i.e., within 14 days of illness onset), definitive interpretation of negative coronavirus antibody tests is possible only for specimens obtained >21 days after onset of symptoms. A reverse transcriptase polymerase chain reaction (RT-PCR) test specific for viral RNA has been positive within the first 10 days after onset of fever in specimens from some SARS patients, but the duration of detectable viremia or viral shedding is unknown. RT-PCR testing can detect SARS-CoV in clinical specimens, including serum, stool, and nasal secretions. Finally, viral culture and isolation have both been used to detect SARS-CoV. Absence of SARS-CoV antibody in serum obtained ≤21 days after illness onset, a negative PCR test, or a negative viral culture does not exclude coronavirus infection.

Reported U.S. cases of SARS still will be classified as suspect or probable; however, these cases can be further classified as laboratory-confirmed or -negative if laboratory data are available and complete, or as laboratory-indeterminate if specimens are not available or testing is incomplete. Obtaining convalescent serum samples to make a final determination about infection with SARS-CoV is critical.

No instances of SARS-CoV infection have been detected in persons who are asymptomatic. However, data are insufficient to exclude the possibility of asymptomatic infection with SARS-CoV and the possibility that such persons can transmit the virus. Investigations of close contacts and health-care workers exposed to SARS patients might provide information about the occurrence of asymptomatic infected persons. Similarly, the clinical manifestations of SARS might extend beyond respiratory illness. As more is learned about SARS-CoV infection, clinical and laboratory criteria will provide a framework for classifying the full spectrum of infection.

This surveillance case definition should be used for reporting and classification purposes only. It should not be used for clinical management or as the only criterion for identifying or testing patients who might have SARS or for instituting infection-control precautions.4,5 This definition will be updated as new data become available or if changes in the epidemiology of SARS occur in the United States.

Footnote: In this updated case definition, Taiwan has been added to the areas with documented or suspected community transmission of SARS; Hanoi, Vietnam is now an area with recently documented or suspected community transmission of SARS.

References
1.
CDC.  Update: Severe acute respiratory syndrome—United States, 2003.  MMWR.2003;52:357-60.
2.
Ksiazek TG, Erdman D, Goldsmith C.  et al.  A novel coronavirus associated with severe acute respiratory syndrome.  N Engl J Med.Available at http://content.nejm.org/cgi/reprint/NEJMoa030781v3.pdf.
3.
Drosten C, Gunther S, Preiser W.  et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.  N Engl J Med.Available at http://content.nejm.org/cgi/reprint/NEJMoa 030747v2.pdf.
4.
CDC.  Updated interim domestic guidelines for triage and disposition of patients who may have severe acute respiratory distress syndrome (SARS). Available at http://www.cdc.gov/ncidod/sars/triage_interim_ guidance.htm.
5.
CDC.  Interim guidance on infection control precautions for patients with suspected severe acute respiratory syndrome (SARS) and close contacts in households. Available at http://www.cdc.gov/ncidod/sars/ic-closecontacts.htm.
×